Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.
Posts Tagged ‘NASDAQ:ASND’
Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter 2023 investor letter.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Here’s Why Baron Health Care Fund Harvested Ascendis Pharma A/S (ASND)
Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2023 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the Q1 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
Top 5 Growth Stocks in Biotech
Headquartered in Bermuda, Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biopharmaceutical company focusing on therapeutics for debilitating disorders.
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2022 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Ascendis Pharma Full Year 2022 Financial Results Conference Call.
What Makes Ascendis Pharma A/S (ASND) an Attractive Investment Choice?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
15 Most Advanced Countries in Europe
Over the course of recent human history, Europe has proven to be the bedrock of innovation.
Here’s the Reason for the Healthy Performance of Ascendis Pharma A/S (ASND)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter.
5 Best Guru Stocks To Buy Now
The Allstate Corporation (NYSE:ALL) is an Illinois-based company that provides property, casualty, and other insurance products in the United States and Canada.
15 Most Valuable Danish Companies in the World
In this article, we will take a look at 15 of the most valuable Danish companies in the world.
Here’s Why Ascendis Pharma A/S (ASND) Became a Detractor in Artisan Partners’ Portfolio
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter investor letter. A copy of the same can be downloaded here.
Artisan Partners ‘Remains Quite Optimistic’ in Ascendis Pharma (ASND)
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded...
Hedge Funds Are Dumping Ascendis Pharma A/S (ASND)
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital
In this piece, we will take a look at the top 5 pharmaceutical stocks to buy according to Peter Kolchinsky's RA Capital. If you want a comprehensive view of Dr.
Here’s Why Artisan Partners Increased its Ascendis Pharma (ASND) Position
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ third quarter 2021 investor letter – a copy of which can be downloaded...
Here is What Hedge Funds Think About Ascendis Pharma A/S (ASND)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change...
Is Ascendis Pharma A/S (ASND) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Should You Consider Investing in Ascendis Pharma (ASND)?
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded...
Is ASND Stock A Buy or Sell?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money ...
Free Stock Pick From Insider Monkey’s Monthly Newsletter
Our premium monthly newsletter costs $449 annually and features my personal stock picks.
Is Ascendis Pharma A/S (ASND) Going to Burn These Hedge Funds?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Why Ascendis Pharma (ASND) Stock is a Compelling Investment Case
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here.
Did Hedge Funds Make The Right Call On Ascendis Pharma A/S (ASND) ?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Should You Avoid Ascendis Pharma A/S (ASND)?
In this article we will check out the progression of hedge fund sentiment towards Ascendis Pharma A/S (NASDAQ:ASND) and determine whether it is a good investment right now.
Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND)
We hate to say this but, we told you so.
How Did Ascendis Pharma A/S (ASND) Compare Against Hedge Fund Darlings in 2019?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Here’s What Hedge Funds Think About Ascendis Pharma A/S (ASND)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Here’s What Hedge Funds Think About Ascendis Pharma A/S (ASND)
How do we determine whether Ascendis Pharma A/S (NASDAQ:ASND) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors ...
Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND)
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals.
Wyndham Hotels & Resorts, Inc. (WH): 2019 Sohn Conference New York Recap
Sohn Conference is my favorite hedge fund event. I haven't missed an event since 2013.
Did Hedge Funds Drop The Ball On Ascendis Pharma A/S (ASND) ?
Is Ascendis Pharma A/S (NASDAQ:ASND) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research.
Glenview Capital Management’s Stock Pitches At 2018 Sohn Conference
Glenview Capital Management is a New York City-based hedge fund, that was launched 18 years ago by Larry Robbins, who previously worked as a trader for billionaire Leon Cooperman...
Best Stock Pick From The 2018 Sohn Conference (Part II)
Nathaniel August recommended a position in Peabody Energy (NYSE:BTU) which “is the largest and least expensive way to participate in the coal market” according to this fund...
What Happened With Light Street’s Glen Kacher’s Best Idea at 2018 Sohn Conference?
It has been almost a year since the last annual Sohn Conference held in New York, and we thought it would be interesting to take a look at how some of the stock pitches presented...
Mangrove Partners’ Nathaniel August’s Best Idea At 2018 Sohn Conference
Nathaniel August’s Mangrove Partners is known for outperforming the market very often; in the first three years since its launching (2010), the fund brought an astonishing return...
Sarissa Capital Management Hires New President
Sarissa Capital Management was one of those rare activist hedge funds, which managed to beat the last year’s tough market environment, returning 15.5%.
Should You Buy Ascendis Pharma A/S (ASND)?
There are several ways to beat the market, and investing in small cap stocks has historically been one of them.
Five Stocks To Buy According To Top Biotech-Focused Funds
Biotechnology is a very interesting industry to invest in, but also very complex.
13D Filing: OrbiMed Advisors and Ascendis Pharma A/S (ASND)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of...
Are Hedge Funds On To Something With Ascendis Pharma A/S (ASND) Bullishness?
Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap...
Ascendis Pharma (ASND): OrbiMed Advisors Adds More Shares
Samuel Isaly just cannot get enough of Ascendis Pharma A/S (NASDAQ:ASND).
OrbiMed Advisors Buys Some More Ascendis Pharma (ASND) Shares
Samuel Isaly's OrbiMed Advisors has stepped up its interest in Ascendis Pharma A/S (NASDAQ:ASND) as reported in a recently-amended filing with the Securities and Exchange Commission...
Hedge Funds Aren’t Crazy About Ascendis Pharma A/S (ASND) Anymore
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers...
Two Healthcare-Focused Funds Buy More Shares Of 2 Promising Companies, While Activist Cashes Out Of IT Company
You don’t necessarily need millions of dollars to invest like an activist investor such as Carl Icahn or Bill Ackman.
Jacob Gottlieb Adds To Position In Ascendis Pharma A/S (ASND); Armistice Capital Increases Stake In Demand Media Inc (DMD)
Is it a good time to buy shares of Ascendis Pharma A/S (NASDAQ:ASND)? Jacob Gottlieb thinks so, since his fund, Visium Asset Management, has significantly increased its holding...
Ascendis Pharma A/S (ASND): Orbimed Advisors Takes Activist Stake in Newly Public Company
Samuel Isaly’s Orbimed Advisors has taken an activist stake in the recently listed Ascendis Pharma A/S (NASDAQ:ASND), an early-stage drug company working on a novel method of...
